<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Topical Methyl Aminolevulinate Photodynamic Therapy in Porokeratosis of Mibelli: An Alternative Treatment for a Refractory Disease.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Topical Methyl Aminolevulinate Photodynamic Therapy in Porokeratosis of Mibelli: An Alternative Treatment for a Refractory Disease." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c632/7992740/6132a8b5666e/ad-31-341-g001.jpg"/> </div> <div class="text-side"> <h1>Topical Methyl Aminolevulinate Photodynamic Therapy in Porokeratosis of Mibelli: An Alternative Treatment for a Refractory Disease.</h1> <p>(A) Erythematous scaly plaque with a raised border on the left buttock. (B) Column of parakeratosis arising from an invagination of the epidermis (H&amp;E, Ã—40). (C) Wood lamp examination after an incubation period of 3 hours during the first methyl aminolevulinate-photodynamic therapy (MAL-PDT). The fluorescence was emitted by the porokeratotic lesion pretreated with methyl aminolevulinate. (D) One month after the first treatment. The second MAL-PDT treatment was performed on the same day. (E) The size of the lesion decreased, and the thread-like elevated border became blurred 3 months after the second treatment.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33911603/" target="_blank">33911603</a></p><p>Type: Benign, Category: Keratinocytic</p>
</div> </div></div></body></html>